EMAIL THIS PAGE TO A FRIEND

The Journal of antimicrobial chemotherapy

Prophylactic treatment with a novel bioadhesive gel formulation containing aciclovir and tenofovir protects from HSV-2 infection.


PMID 25139839

Abstract

Over-the-counter access to an inexpensive, effective topical microbicide could reduce the transmission of HIV and would increase women's control over their health and eliminate the need to obtain their partners' consent for prophylaxis. Chronic infection with herpes simplex virus 2 (HSV-2), also known as human herpes virus 2, has been shown to facilitate HIV infection and speed the progression to immunodeficiency disease. Our objective is to develop a drug formulation that protects against both HSV-2 and HIV infection and adheres to the vaginal surface with extended residence time. We developed a formulation using two approved antiviral active pharmaceutical ingredients, aciclovir and tenofovir, in a novel bioadhesive vaginal delivery platform (designated SR-2P) composed of two polymers, poloxamer 407 NF (Pluronic(®) F-127) and polycarbophil USP (Noveon(®) AA-1). The efficacy of the formulation to protect from HSV-2 infection was tested in vitro and in vivo. In addition to its efficacy, it is essential for a successful microbicide to be non-irritating to the vaginal mucosa. We therefore tested our SR-2P platform gel in the FDA gold-standard microbicide safety model in rabbits and also in a rat vaginal irritation model. Our studies indicated that SR-2P containing 1% aciclovir and 5% tenofovir protects (i) Vero cells from HSV-2 infection in vitro and (ii) mice from HSV-2 infection in vivo. Our results further demonstrated that SR-2P was not irritating in either vaginal irritation model. We conclude that SR-2P containing aciclovir and tenofovir may be a suitable candidate microbicide to protect humans from vaginal HSV-2 infection.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

A0220000
Aciclovir, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001271
Aciclovir for peak identification 1, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001269
Aciclovir for peak identification 2, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
Y0001264
Aciclovir for system suitability, European Pharmacopoeia (EP) Reference Standard
C8H11N5O3
A4669
Acycloguanosine, ≥99% (HPLC), powder
C8H11N5O3
1012065
Acyclovir, United States Pharmacopeia (USP) Reference Standard
C8H11N5O3
PHR1254
Acyclovir, Pharmaceutical Secondary Standard; Certified Reference Material
C8H11N5O3
F2793
D-(−)-Fructose, analytical standard, analytical standard for fructose assay kit, for use with enzymatic assay kit FA20
C6H12O6
47740
D-(−)-Fructose, for microbiology, ≥99.0%
C6H12O6
47748
D-(−)-Fructose, tested according to Ph.Eur.
C6H12O6
69785
DL-Lactic acid, ~90% (T)
C3H6O3
1286504
Fructose, United States Pharmacopeia (USP) Reference Standard
C6H12O6
F0550000
Fructose, European Pharmacopoeia (EP) Reference Standard
C6H12O6
PHR1002
Fructose, Pharmaceutical Secondary Standard; Certified Reference Material
C6H12O6
1356734
Lactic acid, United States Pharmacopeia (USP) Reference Standard
C3H6O3
PHR1215
Lactic acid, Pharmaceutical Secondary Standard; Certified Reference Material
C3H6O3
H5501
Methyl 4-hydroxybenzoate, ReagentPlus®, ≥99.0%, crystalline
C8H8O3
H6654
Methyl 4-hydroxybenzoate, BioXtra, ≥99.0% (titration)
C8H8O3
H3647
Methyl 4-hydroxybenzoate, BioReagent, suitable for insect cell culture
C8H8O3
M8911
Methyl 4-hydroxybenzoate, analytical standard
C8H8O3
54752
Methyl 4-hydroxybenzoate, tested according to Ph.Eur.
C8H8O3
W271004
Methyl 4-hydroxybenzoate, ≥99%, FCC
C8H8O3
47889
Methyl Paraben, analytical standard
C8H8O3
M1650000
Methyl parahydroxybenzoate, European Pharmacopoeia (EP) Reference Standard
C8H8O3
PHR1012
Methylparaben, Pharmaceutical Secondary Standard; Certified Reference Material
C8H8O3
1432005
Methylparaben, United States Pharmacopeia (USP) Reference Standard
C8H8O3